Skip to main content
Caplight Logo









EVerZom

EVerZom

Private
ParisHealthcare & Life Scienceshttps://everzom.com/

Last Round

Series A

Oct 14, 2025

Est. Valuation

$27.15M

Total Funding Raised

$19.15M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

EVerZom is a biotechnology company that develops a biomanufacturing platform for exosome-based therapies for regenerative medicine applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

exosome therapyextracellular vesiclesregenerative medicinebiomanufacturingbioprocessingGMP-compliant manufacturingexosome productionbiotech CDMOcell therapy alternativesEVbiotech partnershipregenerative therapybiotech drug developmentadvanced therapy medicinal productsATMP

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EVerZom Comparables

Compare EVerZom with similar companies based on industry and business-model similarity.

EVerZom comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EXO Biologics
88%
Curexsys GmbH
85%
BREXOGEN Inc.
80%

EVerZom Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 14, 2025
GrantJun 17, 2025
GrantNov 18, 2021
SeedNov 30, 2020

Key People

Founding team and executive leadership

Nicolas Rousseau

Co-Founder - COO

Founding Team

Jeanne Volatron

CEO And Co-founder

Founding Team

EVerZom Investors

Notable investors and investment history

EVerZom investors
InvestorRounds
European Innovation Council FundGrant, Series A
Paris Business AngelsSeries A
Capital Grand EstSeries A
Sorbonne VentureSeries A
BpifranceGrant
Capital CellSeries A
Aloe Private EquitySeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased from 0 to 10, representing 45% of headcount.

  • Jan 7, 2026

    Monthly visitors grew 579% MoM, reaching 2.3K.

EVerZom Filings

Explore SEC and related filing metadata, where available.

EVerZom filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EVerZom's valuation, stock price, and market status.

Is EVerZom a public or private company?

EVerZom is a private company.

What is the current stock price of EVerZom?

EVerZom is a private company with no public stock price. No recent secondary market data is available.

How much is EVerZom worth (valuation)?

Valuation information for EVerZom is not publicly available.

Can I buy EVerZom stock?

EVerZom shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EVerZom's last funding round?

EVerZom's most recent funding round was Series A on October 14, 2025.

Who are the main investors in EVerZom?

Key investors in EVerZom include Capital Grand Est.

Will EVerZom IPO soon?

No public IPO plans have been announced for EVerZom.

How can I track EVerZom secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EVerZom's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range23
Year Founded2019
Last FundingOct 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?